Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study-Reference-Cited by-同舟云学术

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

Published:2020-06 Issue:6 Volume:21 Page:796-807
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Abou-Alfa Ghassan K,Macarulla Teresa,Javle Milind M,Kelley Robin K,Lubner Sam J,Adeva Jorge,Cleary James M,Catenacci Daniel V,Borad Mitesh J,Bridgewater John,Harris William P,Murphy Adrian G,Oh Do-Youn,Whisenant Jonathan,Lowery Maeve A,Goyal Lipika,Shroff Rachna T,El-Khoueiry Anthony B,Fan Bin,Wu Bin,Chamberlain Christina X,Jiang Liewen,Gliser Camelia,Pandya Shuchi S,Valle Juan W,Zhu Andrew X

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review;Boscoe;J Gastrointest Oncol,2019

2. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping;Borger;Oncologist,2012

3. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma;Kipp;Hum Pathol,2012

4. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas;Wang;Oncogene,2013

5. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer;Saha;Nature,2014

Cited by 712 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapeutic strategies in hepatopancreatobiliary cancers;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

2. Hypocrellin A against intrahepatic Cholangiocarcinoma via multi-target inhibition of the PI3K-AKT-mTOR, MAPK, and STAT3 signaling pathways;Phytomedicine;2024-12

3. Clinical and radiological response of Maffucci related enchondromas to mutant IDH1 inhibitor Ivosidenib;Bone;2024-11

4. Exceptional Response to Pembrolizumab in HER2-Positive Gallbladder Carcinoma with High Tumor Mutational Burden;Journal of Gastrointestinal Cancer;2024-09-10

5. Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315);Journal of Clinical Oncology;2024-09-10